- $34.26m
- $41.85m
- $0.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 50.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.22% | ||
| Return on Equity | n/a | ||
| Operating Margin | -3203.98% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | n/a | 0.23 | 0.29 | 0.33 | 1.83 | 6.48 | 43.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Directors
- Zalman Aberman CHM (67)
- Yaky Yanay PRE (50)
- Chen Franco-Yehuda CFO (38)
- Rami Levi DRC (59)
- Varda Shalev DRC (62)
- Doron Birger IND (70)
- Mark Germain IND (70)
- Moria Kwiat IND (41)
- Maital Shemesh-Rasmussen IND (51)
- Doron Shorrer IND (68)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 10th, 2001
- Public Since
- December 10th, 2007
- No. of Shareholders
- 57
- No. of Employees
- 106
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,997,140
- Address
- Matam Park Building 5, HAIFA, 3508409
- Web
- https://pluri-biotech.com/
- Phone
- +972 747108600
- Auditors
- Kesselman & Kesselman
Upcoming Events for PLUR
Pluri Inc Annual Shareholders Meeting
Pluri Inc Annual Shareholders Meeting
Full Year 2025 Pluri Inc Earnings Release
Similar to PLUR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Pluri share price?
As of Today at 22:41 UTC, shares in Pluri are trading at $4.90. This share price information is delayed by 15 minutes.
How has the Pluri share price performed this year?
Shares in Pluri last closed at $4.90 and the price had moved by -13.19% over the past 365 days. In terms of relative price strength the Pluri share price has underperformed the S&P500 Index by -21.72% over the past year.
What are the analyst and broker recommendations for Pluri?
The overall consensus recommendation for Pluri is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pluri dividend yield?
Pluri does not currently pay a dividend.
Does Pluri pay a dividend?
Pluri does not currently pay a dividend.
When does Pluri next pay dividends?
Pluri does not currently pay a dividend.
How do I buy Pluri shares?
To buy shares in Pluri you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pluri?
As of the previous close price of $4.90, shares in Pluri had a market capitalisation of $34.26m.
Where are Pluri shares listed?
Here are the trading details for Pluri:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PLUR
What kind of share is Pluri?
Based on an overall assessment of its quality, value and momentum Pluri is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pluri share price forecast for 2025?
The analyst consensus target price for shares in Pluri is $10.00. That is 104.24% above the last closing price of $4.90.
Analysts covering Pluri currently have a consensus Earnings Per Share (EPS) forecast of -$3.15 for the next financial year.
Find out moreWhat is the trend in the Pluri share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pluri. Over the past six months, its share price has outperformed the S&P500 Index by +1.41%.
As of the last closing price of $4.90, shares in Pluri were trading +0.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pluri PE Ratio?
The Pluri PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pluri?
Pluri's management team is headed by:
- Zalman Aberman - CHM
- Yaky Yanay - PRE
- Chen Franco-Yehuda - CFO
- Rami Levi - DRC
- Varda Shalev - DRC
- Doron Birger - IND
- Mark Germain - IND
- Moria Kwiat - IND
- Maital Shemesh-Rasmussen - IND
- Doron Shorrer - IND